IMDX Insight Molecular Diagnostics Inc.
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1642380 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY520.9%
TTM net income YoY-40.9%
TTM EPS YoY27.5%
Revenue 3-yr CAGR1.0%
Net income 3-yr CAGR—
Margins
Gross margin54.5%
Operating margin-1,392.9%
Net margin-1,380.7%
FCF margin-540.3%
EBITDA margin-1,343.0%
Returns
ROE-23,603.1%
ROA-106.5%
ROIC (approx.)—
Asset turnover0.08x
Leverage & solvency
Liabilities / assets120.9%
Debt / equity—
Current ratio2.79x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.36x
Accruals ratio-68.2%
Payout ratio—
Capex / revenue43.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $4.05M | $1.88M |
| Cost of revenue | $1.75M | $1.05M |
| Gross profit | $2.30M | $740,000 |
| R&D expense | $15.90M | $9.84M |
| SG&A expense | $10.63M | $10.20M |
| Operating income | -$51.12M | -$61.04M |
| Pretax income | — | -$60.66M |
| Income tax | $0 | $0 |
| Net income | -$50.22M | -$60.66M |
| EBITDA | -$48.93M | -$59.48M |
| EPS (basic) | -1.65 | -4.66 |
| EPS (diluted) | -1.65 | -4.66 |
| Weighted avg. shares (diluted) | 30.48M | 13.07M |
| Banking | ||
| Net interest income | -$109,000 | -$84,000 |
| Balance sheet | ||
| Cash & equivalents | $11.58M | $8.64M |
| Receivables | $1.13M | $1.61M |
| Inventory | $446,000 | $410,000 |
| Current assets | $15.31M | $11.76M |
| PP&E, net | $6.43M | $6.32M |
| Intangibles | $0 | $14.61M |
| Total assets | $25.76M | $35.08M |
| Current liabilities | $12.07M | $7.28M |
| Total liabilities | $57.22M | $47.35M |
| Shareholders' equity | -$31.46M | -$12.27M |
| Shares outstanding | 28.68M | 17.45M |
| Cash flow statement | ||
| Operating cash flow | -$22.18M | -$20.69M |
| Capital expenditure | $3.19M | $516,000 |
| Free cash flow | -$25.37M | -$21.20M |
| Investing cash flow | -$3.19M | -$512,000 |
| Financing cash flow | $28.07M | $20.43M |
| Depreciation & amortization | $2.20M | $1.56M |
| Stock-based compensation | $2.22M | $1.75M |
Free plan shows the latest 2 periods; Pro shows all 12 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.